{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-043969","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.975147+00:00","generated_at":"2026-06-29T13:11:05.767162+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics Q2 cash $310.9M; R&D spend doubles; Genmab collaboration on track","bullets":["Cash, cash equivalents, and marketable securities of $310.9M as of June 30, 2021, expected to fund operations through end of 2023.","R&D expenses $19.7M vs $9.2M YoY; G&A expenses $4.1M vs $2.0M YoY; loss from operations $23.8M vs $11.1M YoY.","Lead program BDC-1001 Phase 1/2 data update expected in 2H 2021; Phase 2 monotherapy and combo dose-escalation to initiate in 2H 2021.","Announced R&D collaboration with Genmab for bispecific ISACs: $10M upfront + $15M equity investment; Genmab fully funds three programs through initial proof-of-concept.","Expanded leadership: added VPs in Clinical Development, Early Development, Biometrics, Program Management, HR, and Communications."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-043969","json":"https://secwatch.observer/filing/0001564590-21-043969.json","markdown":"https://secwatch.observer/filing/0001564590-21-043969.md","text":"https://secwatch.observer/filing/0001564590-21-043969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021043969/0001564590-21-043969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021043969/bolt-8k_20210812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:11:05.767162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}